RBC Capital raised the firm’s price target on Amgen (AMGN) to $360 from $335 and keeps an Outperform rating on the shares. The company reported strong Q4 on both top and bottom line, with the beat that was primarily driven by Prolia, Repatha, Evenity, and Uplizna, the analyst tells investors in a research note. On MariTide, Amgen did not offer additional color on part II of the trial that recently read out, but reiterated that there are multiple ways to win in obesity, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target raised to $420 from $389 at TD Cowen
- Amgen price target raised to $309 from $304 at Morgan Stanley
- Amgen price target raised to $345 from $315 at Citi
- Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating
- Closing Bell Movers: AMD down 8% on earnings despite beat